Targeting the latent reservoir to achieve functional HIV cure.

F1000Research

Volumn 5, Issue , 2016, Pages

  Cary, Daniele C ^a   Peterlin, B Matija ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACUTE LEUKEMIA; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CRISPR CAS SYSTEM; DISEASE ERADICATION; DISEASE FREE INTERVAL; DRUG EFFICACY; DRUG TARGETING; GENE INACTIVATION; GENE SILENCING; GENE THERAPY; GENETIC TRANSCRIPTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT VIRUS INFECTION; LYMPH NODE IRRADIATION; REVIEW; SHOCK; SIGNAL TRANSDUCTION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; T LYMPHOCYTE ACTIVATION; VIRUS REACTIVATION;

EID: 85010886914     PISSN: None     EISSN: 20461402     Source Type: Journal    
DOI: 10.12688/F1000RESEARCH.8109.1     Document Type: Review

References (81)

1. UNAIDS: AIDS by the numbers 2015. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2015.
2. Marin B, Thiébaut R, Bucher HC, et al.: Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS. 2009; 23(13): 1743-53.
3. Buzón MJ, Massanella M, Llibre JM, et al.: HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med. 2010; 16(4): 460-5.
4. Lorenzo-Redondo R, Fryer HR, Bedford T, et al.: Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature. 2016; 530(7588): 51-6.
5. Chun TW, Stuyver L, Mizell SB, et al.: Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997; 94(24): 13193-7.
6. Finzi D, Hermankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997; 278(5341): 1295-300.
7. Wong JK, Hezareh M, Günthard HF, et al.: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997; 278(5341): 1291-5.
8. Day CL, Kaufmann DE, Kiepiela P, et al.: PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006; 443(7109): 350-4.
9. Kaufmann DE, Kavanagh DG, Pereyra F, et al.: Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol. 2007; 8(11): 1246-54.
10. Callahan MK, Wolchok JD: At the bedside: CTLA-4-and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol. 2013; 94(1): 41-53.
11. Jones RB, Walker BD: HIV-specific CD8+ T cells and HIV eradication. J Clin Invest. 2016; 126(2): 455-63.
12. Renga B, Francisci D, D'Amore C, et al.: HIV-1 infection is associated with changes in nuclear receptor transcriptome, pro-inflammatory and lipid profile of monocytes. BMC Infect Dis. 2012; 12: 274.
13. Yadav A, Collman RG: CNS inflammation and macrophage/microglial biology associated with HIV-1 infection. J Neuroimmune Pharmacol. 2009; 4(4): 430-47.
14. Brooks DG, Ha SJ, Elsaesser H, et al.: IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. Proc Natl Acad Sci U S A. 2008; 105(51): 20428-33.
15. Rigopoulou EI, Abbott WG, Haigh P, et al.: Blocking of interleukin-10 receptor-a novel approach to stimulate T-helper cell type 1 responses to hepatitis C virus. Clin Immunol. 2005; 117(1): 57-64.
16. Levy Y, Lacabaratz C, Weiss L, et al.: Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest. 2009; 119(4): 997-1007.
17. Scripture-Adams DD, Brooks DG, Korin YD, et al.: Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol. 2002; 76(24): 13077-82.
18. Lévy Y, Sereti I, Tambussi G, et al.: Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebocontrolled, multicenter study. Clin Infect Dis. 2012; 55(2): 291-300.
19. Seay K, Church C, Zheng JH, et al.: In Vivo Activation of Human NK Cells by Treatment with an Interleukin-15 Superagonist Potently Inhibits Acute In Vivo HIV-1 Infection in Humanized Mice. J Virol. 2015; 89(12): 6264-74.
20. Bartholomeeusen K, Xiang Y, Fujinaga K, et al.: Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein. J Biol Chem. 2012; 287(43): 36609-16.
21. Yu W, Ramakrishnan R, Wang Y, et al.: Cyclin T1-dependent genes in activated CD4+ T and macrophage cell lines appear enriched in HIV-1 co-factors. PLoS One. 2008; 3(9): e3146.
22. Bartholomeeusen K, Fujinaga K, Xiang Y, et al.: Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription. J Biol Chem. 2013; 288(20): 14400-7.
23. Rasmussen TA, Schmeltz Søgaard O, Brinkmann C, et al.: Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother. 2013; 9(5): 993-1001.
24. Wei DG, Chiang V, Fyne E, et al.: Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog. 2014; 10(4): e1004071.
25. Contreras X, Schweneker M, Chen CS, et al.: Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem. 2009; 284(11): 6782-9.
26. Routy JP, Tremblay CL, Angel JB, et al.: Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med. 2012; 13(5): 291-6.
27. Boehm D, Calvanese V, Dar RD, et al.: BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle. 2013; 12(3): 452-62.
28. Spina CA, Anderson J, Archin NM, et al.: An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog. 2013; 9(12): e1003834.
29. Blazkova J, Chun TW, Belay BW, et al.: Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4+ T cells from infected individuals receiving effective antiretroviral therapy. J Infect Dis. 2012; 206(5): 765-9.
30. Archin NM, Liberty AL, Kashuba AD, et al.: Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012; 487(7408): 482-5.
31. Korin YD, Brooks DG, Brown S, et al.: Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol. 2002; 76(16): 8118-23.
32. Pérez M, de Vinuesa AG, Sanchez-Duffhues G, et al.: Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency. Curr HIV Res. 2010; 8(6): 418-29.
33. Hori T, Barnor J, Huu TN, et al.: Procyanidin trimer C1 derived from Theobroma cacao reactivates latent human immunodeficiency virus type 1 provirus. Biochem Biophys Res Commun. 2015; 459(2): 288-93.
34. Wang C, Yang S, Lu H, et al.: A Natural Product from Polygonum cuspidatum Sieb. Et Zucc. Promotes Tat-Dependent HIV Latency Reversal through Triggering P-TEFb's Release from 7SK snRNP. PLoS One. 2015; 10(11): e0142739.
35. Beans EJ, Fournogerakis D, Gauntlett C, et al.: Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo. Proc Natl Acad Sci U S A. 2013; 110(29): 11698-703.
36. DeChristopher BA, Loy BA, Marsden MD, et al.: Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. Nat Chem. 2012; 4(9): 705-10.
37. Wender PA, Nakagawa Y, Near KE, et al.: Computer-guided design, synthesis, and protein kinase C affinity of a new salicylate-based class of bryostatin analogs. Org Lett. 2014; 16(19): 5136-9.
38. Pandeló José D, Bartholomeeusen K, da Cunha RD, et al.: Reactivation of latent HIV-1 by new semi-synthetic ingenol esters. Virology. 2014; 462-463: 328-39.
39. Jiang G, Mendes EA, Kaiser P, et al.: Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cd-NF-κB signaling. AIDS. 2014; 28(11): 1555-66.
40. Abreu CM, Price SL, Shirk EN, et al.: Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR. PLoS One. 2014; 9(5): e97257.
41. Jiang G, Mendes EA, Kaiser P, et al.: Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation. PLoS Pathog. 2015; 11(7): e1005066.
42. Darcis G, Kula A, Bouchat S, et al.: An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression. PLoS Pathog. 2015; 11(7): e1005063.
43. Laird GM, Bullen CK, Rosenbloom DI, et al.: Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest. 2015; 125(5): 1901-12.
44. Scully E, Alter G: NK Cells in HIV Disease. Curr HIV/AIDS Rep. 2016; 13(2): 85-94.
45. Jones RB, O'Connor R, Mueller S, et al.: Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes. PLoS Pathog. 2014; 10(8): e1004287.
46. Cicin-Sain L, Sylwester AW, Hagen SI, et al.: Cytomegalovirus-specific T cell immunity is maintained in immunosenescent rhesus macaques. J Immunol. 2011; 187(4): 1722-32.
47. Hansen SG, Ford JC, Lewis MS, et al.: Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature. 2011; 473(7348): 523-7.
48. Hansen SG, Sacha JB, Hughes CM, et al.: Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science. 2013; 340(6135): 1237874.
49. Halper-Stromberg A, Nussenzweig MC: Towards HIV-1 remission: potential roles for broadly neutralizing antibodies. J Clin Invest. 2016; 126(2): 415-23.
50. Chun TW, Murray D, Justement JS, et al.: Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir. Proc Natl Acad Sci U S A. 2014; 111(36): 13151-6.
51. Halper-Stromberg A, Lu CL, Klein F, et al.: Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell. 2014; 158(5): 989-99.
52. Bruel T, Guivel-Benhassine F, Amraoui S, et al.: Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nat Commun. 2016; 7: 10844.
53. Grupp SA, Kalos M, Barrett D, et al.: Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368(16): 1509-18.
54. Maude SL, Frey N, Shaw PA, et al.: Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16): 1507-17.
55. Gavegnano C, Detorio M, Montero C, et al.: Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. Antimicrob Agents Chemother. 2014; 58(4): 1977-86.
56. Haile WB, Gavegnano C, Tao S, et al.: The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model. Neurobiol Dis. 2016; pii: S0969-9961(16)30028-6.
57. Starzl TE, Weil R 3rd, Iwatsuki S, et al.: The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet. 1980; 151(1): 17-26.
58. Bunjes D, Hardt C, Röllinghoff M, et al.: Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2. Eur J Immunol. 1981; 11(8): 657-61.
59. Andrieu JM, Even P, Venet A, et al.: Effects of cyclosporin on T-cell subsets in human immunodeficiency virus disease. Clin Immunol Immunopathol. 1988; 47(2): 181-98.
60. Markowitz M, Vaida F, Hare CB, et al.: The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection. J Infect Dis. 2010; 201(9): 1298-302.
61. Rizzardi GP, Harari A, Capiluppi B, et al.: Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest. 2002; 109(5): 681-8.
62. Mousseau G, Kessing CF, Fromentin R, et al.: The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency. MBio. 2015; 6(4): e00465.
63. Mediouni S, Jablonski J, Paris JJ, et al.: Didehydro-cortistatin A inhibits HIV-1 Tat mediated neuroinflammation and prevents potentiation of cocaine reward in Tat transgenic mice. Curr HIV Res. 2015; 13(1): 64-79.
64. Hütter G, Nowak D, Mossner M, et al.: Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009; 360(7): 692-8.
65. Tebas P, Stein D, Tang WW, et al.: Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014; 370(10): 901-10.
66. Ye L, Wang J, Beyer AI, et al.: Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection. Proc Natl Acad Sci U S A. 2014; 111(26): 9591-6.
67. Wang W, Ye C, Liu J, et al.: CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection. PLoS One. 2014; 9(12): e115987.
68. Schumann K, Lin S, Boyer E, et al.: Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci U S A. 2015; 112(33): 10437-42.
69. Hou P, Chen S, Wang S, et al.: Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. Sci Rep. 2015; 5: 15577.
70. Chan E, Towers GJ, Qasim W: Gene therapy strategies to exploit TRIM derived restriction factors against HIV-1. Viruses. 2014; 6(1): 243-63.
71. Carthagena L, Parise MC, Ringeard M, et al.: Implication of TRIM alpha and TRIMCyp in interferon-induced anti-retroviral restriction activities. Retrovirology. 2008; 5: 59.
72. Neagu MR, Ziegler P, Pertel T, et al.: Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components. J Clin Invest. 2009; 119(10): 3035-47.
73. Walker JE, Chen RX, McGee J, et al.: Generation of an HIV-1-resistant immune system with CD34+ hematopoietic stem cells transduced with a triplecombination anti-HIV lentiviral vector. J Virol. 2012; 86(10): 5719-29.
74. Wright AV, Nuñez JK, Doudna JA: Biology and Applications of CRISPR Systems: Harnessing Nature's Toolbox for Genome Engineering. Cell. 2016; 164(1-2): 29-44.
75. Ebina H, Misawa N, Kanemura Y, et al.: Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep. 2013; 3: 2510.
76. Hu W, Kaminski R, Yang F, et al.: RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci U S A. 2014; 111(31): 11461-6.
77. Wang G, Zhao N, Berkhout B, et al.: CRISPR-Cas9 Can Inhibit HIV-1 Replication but NHEJ Repair Facilitates Virus Escape. Mol Ther. 2016; 24(3): 522-6.
78. Zhang Y, Yin C, Zhang T, et al.: CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs. Sci Rep. 2015; 5: 16277.
79. Saayman SM, Lazar DC, Scott TA, et al.: Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex. Mol Ther. 2016; 24(3): 488-98.
80. Limsirichai P, Gaj T, Schaffer DV: CRISPR-mediated Activation of Latent HIV-1 Expression. Mol Ther. 2016; 24(3): 499-507.
81. Massanella M, Richman DD: Measuring the latent reservoir in vivo. J Clin Invest. 2016; 126(2): 464-72.